14 April 2017
: Case report
Mycophenolate Mofetil and Pulmonary Fibrosis After Kidney Transplantation: A Case Report
Unusual or unexpected effect of treatment, Rare disease, Adverse events of drug therapy, Educational Purpose (only if useful for a systematic review or synthesis)
Kazuhiro Takahashi1ABCDEF*, Pauline Go1ABCDEF, Chad H. Stone2D, Mohamed Safwan1E, Krishna G. Putchakayala1BC, William J. Kane1E, Lauren E. Malinzak1E, Dean Y. Kim1E, Jason E. Denny1ACDEFGDOI: 10.12659/AJCR.902380
Am J Case Rep 2017; 18:399-404
Abstract
BACKGROUND: Mycophenolate mofetil (MMF) induced lung disease has been described in only a few isolated reports. We report a case of fatal respiratory failure associated with MMF after kidney transplantation.
CASE REPORT: A 50-year-old Hispanic male with a history of end-stage renal disease secondary to hypertension underwent deceased donor kidney transplantation. His preoperative evaluations were normal except for a chest x-ray which showed bilateral interstitial opacities. Tacrolimus and MMF were started on the day of surgery. His postoperative course was uneventful and he was discharged on postoperative day 5. One month later, he presented with shortness of breath and a cough with blood-tinged sputum. His respiratory condition deteriorated rapidly, requiring intubation. Chest computer tomography (CT) demonstrated patchy ground-glass opacities with interlobular septal thickening. Comprehensive pulmonary, cardiac, infectious, and immunological evaluations were all negative. Open lung biopsy revealed extensive pulmonary fibrosis with no evidence of infection. He temporarily improved after discontinuation of tacrolimus and MMF, however, on resuming MMF his respiratory status deteriorated again and he subsequently died from hypoxic respiratory failure.
CONCLUSIONS: An awareness of pulmonary lung disease due to MMF is important to prevent adverse outcomes after organ transplantation. MMF must be used with utmost care in recipients with underlying lung disease as their pulmonary condition might make them more susceptible to any harmful effects of MMF.
Keywords: Abnormalities, Drug-Induced, Immunosuppressive Agents, Tacrolimus
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946488
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946876
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946560
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946727
Most Viewed Current Articles
21 Jun 2024 : Case report
96,182
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
52,159
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
20 Nov 2023 : Case report
31,026
DOI :10.12659/AJCR.941424
Am J Case Rep 2023; 24:e941424
18 Feb 2024 : Case report
23,365
DOI :10.12659/AJCR.943030
Am J Case Rep 2024; 25:e943030